Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wysenski Retirement, New Chief Legal Officer Add Another Layer To CF Data-Error Story At Vertex

This article was originally published in The Pink Sheet Daily

Executive Summary

While Wall Street seems to have forgiven Vertex for mistakenly reporting better breathing-improvement data than actually was the case for an experimental cystic fibrosis drug, questions about executives who sold stock before the data correction are raising eyebrows in Congress and at the SEC.

Advertisement

Related Content

Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074266

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel